Thryv Therapeutics has licensed a new class of SGK1 inhibitor compounds from Spanish researchers, extending its platform toward Parkinson's and Alzheimer's disease.
#Biotech #Biotechnology #Health #Alzheimer #Parkinsons
#Research
Follow Us for More!
Disclaimer: This is NOT a financial advice
Thryv Therapeutics has licensed a new class of SGK1 inhibitor compounds from Spanish researchers, extending its platform toward Parkinson's and Alzheimer's disease. #Biotech #Biotechnology #Health #Alzheimer #Parkinsons #Research Follow Us for More! Disclaimer: This is NOT a financial advice
0 vue
Publié le 08/09/2026 07:34
0:10
Thryv Therapeutics has licensed a new class of SGK1 inhibitor compounds from Spanish researchers, extending its platform toward Parkinson's and Alzheimer's disease.
#Biotech #Biotechnology #Health #Alzheimer #Parkinsons
#Research
Follow Us for More!
Disclaimer: This is NOT a financial advice
0 commentaire
?